| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,506,379 ) |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 5 | NIH | 3/27/2024 | $107,065 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 000 | 4 | NIH | 3/19/2024 | $282,070 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 5 | NIH | 3/27/2024 | $143,548 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI162001 | Mechanisms of type I IFN signaling and HIV risk in the female genital tract | 000 | 4 | NIH | 3/18/2024 | $122,682 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 18 | NIH | 11/2/2023 | $110,564 |
| | 2024 | 2024 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 18 | NIH | 11/2/2023 | $740,450 |
| | 2024 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 000 | 1 | NIH | 10/16/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,673,620 ) |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 4 | NIH | 3/15/2023 | $141,990 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UG1CA284671 | CAPRISA CASCADE Clinical Trials Network Clinical Research Site | 000 | 1 | NIH | 9/5/2023 | $216,000 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 17 | NIH | 11/21/2022 | $866,529 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 004 | 17 | NIH | 5/31/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 004 | 17 | NIH | 5/31/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 004 | 17 | NIH | 5/31/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 17 | NIH | 2/7/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 17 | NIH | 2/7/2023 | $0 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 17 | NIH | 5/19/2023 | $110,186 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 17 | NIH | 5/19/2023 | $151,057 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 003 | 17 | NIH | 5/19/2023 | $866,529 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 17 | NIH | 11/21/2022 | $110,186 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 001 | 4 | NIH | 8/3/2023 | $303,515 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 002 | 4 | NIH | 8/4/2023 | $369,940 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 000 | 3 | NIH | 5/8/2023 | $129,848 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI162001 | Mechanisms of type I IFN signaling and HIV risk in the female genital tract | 000 | 3 | NIH | 3/2/2023 | $124,785 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 4 | NIH | 3/15/2023 | $170,999 |
| | 2023 | 2023 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | K43TW011437 | Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa | 000 | 5 | NIH | 4/11/2023 | $112,056 |
| | 2023 | 2020 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 14 | NIH | 10/17/2022 | $0 |
| | 2023 | 2019 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | G11TW010553 | CAPRISA Research Administration and Management Training Program | 000 | 3 | NIH | 11/9/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,949,309 ) (Continued on the next page) |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 000 | 3 | NIH | 8/3/2022 | $192,499 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 16 | NIH | 6/14/2022 | $0 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 16 | NIH | 6/3/2022 | $155,668 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 001 | 16 | NIH | 6/3/2022 | $675,893 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 16 | NIH | 11/15/2021 | $243,481 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 000 | 16 | NIH | 11/15/2021 | $1,057,165 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | UM1AI069469 | KwaZulu-Natal Clinical Trials Unit | 002 | 16 | NIH | 6/14/2022 | $0 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI152142 | Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | 000 | 3 | NIH | 8/3/2022 | $122,912 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01AI162001 | Mechanisms of type I IFN signaling and HIV risk in the female genital tract | 000 | 2 | NIH | 3/4/2022 | $130,287 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 3 | NIH | 5/19/2022 | $192,345 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | R01HD102052 | Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health | 000 | 3 | NIH | 5/19/2022 | $133,198 |
| | 2022 | 2022 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | K43TW011437 | Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa | 003 | 4 | NIH | 4/4/2022 | $107,826 |
| | 2022 | 2021 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | K43TW011437 | Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa | 002 | 3 | NIH | 4/4/2022 | $0 |
| | 2022 | 2020 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | K43TW011437 | Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa | 001 | 2 | NIH | 4/4/2022 | $0 |
| | 2022 | 2019 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | | | | ZAF | K43TW011437 | Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa | 000 | 1 | NIH | 4/4/2022 | $0 |
| | 2022 | 2013 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | province | | | ZAF | NU2GPS001350 | CAPRISA AIDS TREATMENT PROGRAMME | 07 | 6 | CDC | 4/8/2022 | $0 |
| | 2022 | 2013 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | province | | | ZAF | NU2GPS001350 | CAPRISA AIDS TREATMENT PROGRAMME | 07 | 6 | CDC | 4/8/2022 | $0 |
| | 2022 | 2013 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | province | | | ZAF | NU2GPS001350 | CAPRISA AIDS TREATMENT PROGRAMME | 07 | 6 | CDC | 4/8/2022 | $0 |
| | 2022 | 2012 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | province | | | ZAF | NU2GPS001350 | CAPRISA AIDS TREATMENT PROGRAMME | 07 | 6 | CDC | 4/8/2022 | $0 |
| | 2022 | 2012 | CENTRE FOR THE AIDS PROGRAM OF RESEARCH IN SOUTH AFRICA | 719 UMBILO ROAD | DURBAN | province | | | ZAF | NU2GPS001350 | CAPRISA AIDS TREATMENT PROGRAMME | 07 | 6 | CDC | 4/8/2022 | $0 |
|
